

1 **Fourteen-days Evolution of COVID-19 Symptoms During**  
2 **the Third Wave in Non-vaccinated Subjects and Effects of**  
3 **Hesperidin Therapy: A randomized, double-blinded,**  
4 **placebo-controlled study.**

5 Jocelyn Dupuis, MD, PhD<sup>a,b</sup>, Pierre Laurin MSc Pharm<sup>c</sup>, Jean-Claude Tardif, MD<sup>a,b</sup>, Leslie  
6 Hausermann, PhD<sup>a</sup>, Camille Rosa MSc<sup>d</sup>, Marie-Claude Guertin PhD<sup>d</sup>, Karen Thibaudeau PhD<sup>c</sup>,  
7 Lyne Gagnon PhD<sup>c</sup>, Frank Cesari BSc<sup>c</sup>, Martin Robitaille PhD<sup>c</sup>, John E. Moran, MD<sup>c</sup>

8

9

10

11

12

13

**Brief Title:** COVID-19 symptoms and hesperidin

14

15

16

17 From the <sup>a</sup>Montreal Heart Institute Research Center, Montreal, Quebec, Canada; <sup>b</sup>Department of  
18 Medicine of Université de Montréal, Montreal, Quebec, Canada; <sup>c</sup>Ingenew Pharmaceuticals,  
19 Montreal, Quebec, Canada; <sup>d</sup>Montreal Health Innovations Coordination Center, Montreal,  
20 Quebec, Canada.

21

22

23

24 \*Corresponding author: Jocelyn Dupuis MD, PhD, Research Center, Montreal Heart Institute,  
25 5000 Belanger Street, Montreal, Qc H1T 1C8, Canada. Tel. 514-376-3330. Fax 514-376-1355  
26 E-mail: dupuisj@icloud.com

27 **ABSTRACT**

28 COVID-19 symptoms can cause substantial disability, yet no therapy can currently reduce  
29 their frequency or duration. We conducted a double-blind placebo-controlled trial of hesperidin  
30 1000 mg once-daily for 14 days in 216 symptomatic non-vaccinated COVID-19 subjects.  
31 Thirteen symptoms were recorded after 3, 7, 10 and 14 days. The primary endpoint was the  
32 proportion of subjects with any of four cardinal (group A) symptoms: fever, cough, shortness of  
33 breath or anosmia. At baseline, symptoms in decreasing frequency were: cough (53.2%),  
34 weakness (44.9%), headache (42.6%), pain (35.2%), sore throat (28.7%), runny nose (26.9%),  
35 chills (22.7%), shortness of breath (22.2%), anosmia (18.5%), fever (16.2%), diarrhea (6.9%),  
36 nausea/vomiting (6.5%) and irritability/confusion (3.2%). Group A symptoms in the placebo vs  
37 hesperidin group was 88.8% vs 88.5% (day 1) and reduced to 58.5 vs 49.4 % at day 14 (OR 0.69,  
38 95% CI 0.38–1.27,  $p = 0.23$ ). At day 14, 15 subjects in the placebo group and 28 in the  
39 hesperidin group failed to report their symptoms. In an attrition bias analysis imputing “no  
40 symptoms” to missing values, the hesperidin group shows reduction of 14.5 % of group A  
41 symptoms from 50.9% to 36.4% (OR: 0.55, 0.32–0.96,  $p = 0.03$ ). Anosmia, the most frequent  
42 persisting symptom (29.3%), was lowered by 7.3% at 25.3 % in the hesperidin group vs 32.6% in  
43 the placebo group ( $p = 0.29$ ). Mean number of symptoms in placebo and hesperidin was  $5.10 \pm$   
44  $2.26$  vs  $5.48 \pm 2.35$  (day 1) and  $1.40 \pm 1.65$  vs  $1.38 \pm 1.76$  (day 14) ( $p = 0.92$ ). In conclusion,  
45 most non-vaccinated COVID-19 infected subjects remain symptomatic after 14 days with  
46 anosmia being the most frequently persisting symptom. Hesperidin 1g daily may help reduce  
47 group A symptoms. Earlier treatment of longer duration and/or higher dosage should be tested.

48

49 **Key Words:** flavonoid ▪ COVID-19 ▪ viral infection ▪ therapy ▪ hesperidin ▪ symptom

## 50 **Introduction**

51 Since the end of December 2019, the COVID-19 pandemic led to important worldwide morbidity  
52 and mortality. Despite the success of vaccination, a substantial proportion of the world  
53 population is still awaiting immunization and therefore at risk of getting infected with the  
54 inherent risk of viral mutations that could lead to vaccine resistant strains of the virus. Most  
55 infected subjects report symptoms of varying severity that can become debilitating and persist for  
56 prolonged periods in a substantial proportion. Currently, no therapy that has been shown to  
57 reduce the burden and length of COVID-19 symptoms in non-hospitalized subjects.

58 COVID-19 is due to an infection by a novel beta-coronavirus, identified as 2019-nCoV  
59 [1], now known as Severe Acute Respiratory Syndrome – Coronavirus 2 (SARS-CoV-2), whose  
60 entry into cells has been shown to be dependant of the angiotensin converting enzyme 2 (ACE2)  
61 [2]. In a meta-analysis of 212 studies, Lie et al. [3] reported that the most common symptoms of  
62 COVID-19 were fever (78.8%), cough (53.9%) and malaise (37.9%). Other reported symptoms  
63 were fatigue (32.3%), expectoration (24.2%), myalgia (21.3%), shortness of breath (18.99%),  
64 chills (15.7%), diarrhea (9.5%), chest pain (9%), rhinorrhea (7.5%), vomiting (4.7%) and  
65 abdominal pain (4.5%). Furthermore, patients with a severe form of the disease were more  
66 subject to shortness of breath, abdominal pain, chills and dizziness than patients with a non-  
67 severe form. Studies also reported taste and smell dysfunction, such as anosmia, as a common  
68 symptom in people infected with COVID-19 [4, 5]. Some subjects at higher risk may show  
69 marked inflammation in response to the infection, referred to as the cytokine storm, leading to  
70 greater disease severity with acute respiratory distress and risk of hospital admission and death  
71 [6, 7]. The evolution of COVID-19 symptoms in non-hospitalized and non-vaccinated subjects  
72 during the third wave of the pandemic has not been reported. Compared to the first and second  
73 waves, large scale PCR testing became available during the third wave and was largely publicised

74 and encouraged in all possibly infected subjects. The true proportion and evolution of symptoms  
75 may therefore differ from what was reported in previously more selected populations.

76 Hesperidin, a flavonoid naturally present in the peel of citrus fruits inhibits the 3-  
77 chymotrypsin like protease 3 (3CLpro) involved in SARS-CoV2 replication [8]. As well,  
78 hesperidin was reported to target the binding interface between the Spike protein of SARS-CoV-  
79 2 and the ACE2 receptor, potentially preventing the interaction of ACE 2 with the Spike regional  
80 binding domain (RBD) [9].

81 *In vivo* experimentation in rats infected with the H1N1 virus revealed that hesperidin  
82 effectively reduced lung impairment and suppressed pulmonary inflammation by reducing pro-  
83 inflammatory cytokines and recruitment of pro-inflammatory cells [10]. These anti-inflammatory  
84 and pulmonary protective effects were also reported in rats and mice with ventilator- and  
85 lipopolysaccharides-induced acute lung injury, respectively [11, 12]. Furthermore, evidence of  
86 cardioprotective and neuroprotective effects of flavanones, through their anti-oxidant and anti-  
87 inflammatory actions, were reviewed within the last decade and suggest the therapeutic potential  
88 of these compounds in conditions associated with inflammation and oxidative stress [13-15].

89 Considering its possible effects on SARS-CoV-2 entry into the cells and replication, as  
90 well as its anti-inflammatory action and its effectiveness in animal models of acute respiratory  
91 distress, hesperidin may be of interest in the treatment of COVID-19 related symptoms and  
92 complications. This study was designed to determine the effects of 14 days hesperidin treatment  
93 on the burden of COVID-19 symptoms in non-hospitalized subjects.

94

95

## 96 **METHODS**

### 97 **Participants**

98 This was a phase 2, randomized, double-blind, placebo-controlled study conducted at the  
99 Montreal Heart Institute (MHI) and comparing the effects of hesperidin (1000 mg once daily) and  
100 matching placebo (ratio 1:1) on COVID-19 symptoms during 14 days in participants infected  
101 with COVID-19 (detailed protocol is presented in S1 Protocol). Health Canada gave its  
102 authorization to conduct the study, which was also reviewed and approved by the Montreal Heart  
103 Institute Research and Ethics Committees (2021-2841). The study of hesperidin on COVID-19  
104 symptoms (HESPERIDIN) was registered at [clinicaltrials.gov](https://clinicaltrials.gov) (NCT04715932). A total of 216  
105 subjects were recruited between February 18 and May 20, 2021 in the province of Quebec,  
106 Canada. All subjects were recruited by the Montreal Heart Institute research center and the study  
107 was coordinated by the Montreal Health Innovations Coordinating Center (MHICC).

108 Non-hospitalized male and female subjects of at least 18 years of age with a positive  
109 diagnosis of COVID-19 confirmed by polymerase chain reaction (PCR) testing within the last 48  
110 hours and with at least one COVID-19 symptom were included. Female participants had to be  
111 without childbearing potential (postmenopausal for at least one year or surgically sterile) or with  
112 childbearing potential and practicing at least one method of contraception. Subjects were  
113 excluded if they were currently hospitalized or under immediate consideration for hospitalization,  
114 currently in shock or with hemodynamic instability, or undergoing chemotherapy for cancer.  
115 Other exclusion criteria for participants were: unable to take their oral temperature daily; having  
116 received a least one dose of the COVID-19 vaccine; pregnant (or considering becoming pregnant  
117 during the study) or breastfeeding women; taking anticoagulant or antiplatelet medications;  
118 bleeding disorders; and within 2 weeks of received or planned surgery. People with a regular  
119 consumption of natural products containing more than 150 mg of hesperidin or regular  
120 consumption of more than one glass of orange juice per day were also excluded, as were subjects  
121 with known allergy to any of the medicinal and non-medicinal ingredients of the study drug.

122 This was a no-contact study with the screening, randomization and follow-ups at day 3, 7,  
123 10 and 14 done exclusively by phone. All randomized subjects signed an electronic informed  
124 consent form using the DocuSign online service. The study medication and material were  
125 delivered to the patients' home and included an oral electronic thermometer (Physio logic<sup>®</sup>  
126 Acuflex Pro) and a daily symptoms log. Allocation was performed through a randomization list  
127 generated by the MHICC (blocks sequence was fixed with block size of 4) and provided to the  
128 MHI pharmacists who dispensed the medication (hesperidin or placebo) according to the list after  
129 randomization of the participants by the study coordinators, keeping participants, investigators  
130 and staff blinded to drug assignment for the whole study duration. The symptoms log listed 13  
131 COVID-19 symptoms including the temperature readings in degrees Celsius. Participants were  
132 asked to take two capsules (500 mg each) of study medication once daily at bedtime on an empty  
133 stomach. They were requested to record their symptoms and temperature daily in the symptoms  
134 log and return it to the study team at the end of their participation. At each follow-up call, the  
135 information recorded in the symptoms log was captured in an electronic case report form (InForm  
136 V 6.0, Oracle Health Sciences) by the study team. The trial ended according to protocol, namely  
137 after last patient last visit. The hesperidin capsules and matching placebo were kindly provided  
138 by Valeo Pharma (Kirkland, Quebec, Canada).

139  
140 **Outcomes**

141 The primary endpoint was the proportion of subjects with any of the following cardinal  
142 COVID-19 symptoms: fever, cough, shortness of breath or anosmia at day 3, 7, 10 and 14. These  
143 symptoms are referred to as group A symptoms in the province of Quebec, Canada. The  
144 secondary endpoints were: 1) The mean number of all COVID-19 symptoms (range 0-13) at day  
145 3, 7, 10 and 14; 2) Duration of COVID-19 symptoms, defined as the number of days between

146 first symptom and complete disappearance of any symptom; 3) For each 13 COVID-19  
147 symptoms listed in the symptoms log (recent cough or aggravation of chronic cough, fever,  
148 chills, sore throat, runny nose, shortness of breath, nausea/vomiting, headache, general weakness,  
149 pain, irritability/confusion, diarrhea and anosmia defined as sudden loss of smell), the proportion  
150 of subjects with the symptom at day 3, 7, 10 and 14. Fever was defined as a temperature of  $> 38.0$   
151  $^{\circ}\text{C}$  by oral temperature using the supplied electronic thermometer.

152 The study also included two exploratory endpoints: 1) For each COVID-19 listed in the  
153 symptoms log, proportion of subjects with the symptom on a daily basis; and: 2) Composite of  
154 COVID-19 related hospitalization, mechanic ventilation or death in the 14 days following  
155 randomization.

156 The safety data were reviewed by a fully independent 3-member Data and Safety  
157 Monitoring Board (DSMB) after randomization of 50 subjects. Serious adverse events were  
158 reported to the DSMB on a weekly basis after their first meeting.

159

## 160 **Statistical analyses**

161 Sample size was based on the proportion of subjects with any of the following group A COVID-  
162 19 symptoms: fever, cough, shortness of breath or anosmia at day 7. We assumed that 50% of  
163 placebo subjects would be symptomatic at this time point. These symptoms, referred to as group  
164 A symptoms in Quebec, are among the most frequent COVID-19 symptoms and are more  
165 objectively assessable. These symptoms were used as a diagnostic criterion in the  
166 epidemiological definition of COVID-19 prior to the widespread use and availability of PCR  
167 testing. Using a two-sided 0.05 significance level, considering achieving an 80% power to detect  
168 an absolute difference of 20% between both groups in the proportion of symptomatic

169 participants, and factoring in a 15% drop out rate, we determined that 216 participants (108 per  
170 group) were required to complete the study.

171 Efficacy analyses were based on an intent-to-treat (ITT) principle. All participants who  
172 received the medication were included in the ITT population. The primary analysis compared the  
173 proportions of subjects between both treatment groups using a generalized linear mixed model  
174 (GLMM), more precisely, a repeated binary logistic regression model with terms for treatment  
175 group (placebo, hesperidin), time (3, 7, 10 and 14 days) and treatment group x time interaction.  
176 Contrasts under this model allowed for the comparisons of the proportions at each time point.  
177 Then, for secondary analyses, number of COVID-19 symptoms was compared between treatment  
178 groups using another GLMM, namely a repeated Poisson regression model with similar terms for  
179 group, time and interaction. Rate ratios are presented with 95% confidence intervals and p-  
180 values. Duration of COVID-19 symptoms were compared using a log rank test with Kaplan-  
181 Meier curves. Subjects who still had at least one symptom at their last assessment were censored  
182 at the day of this last assessment. The statistical approach used for primary endpoint was also  
183 used to compare individual COVID-19 symptoms over time. Composite of COVID-19-related  
184 hospitalization, mechanic ventilation or death were compared between both groups using a chi-  
185 square test. Statistical analyses were described in a statistical analysis plan that was approved  
186 prior to database lock and unblinding.

187 Safety of hesperidin was evaluated with descriptive statistics on adverse events and  
188 serious adverse events broken down by groups and presented on the safety population of all  
189 subjects who took at least one dose of the study medication.

190 To account for a possible attrition bias and evaluate its impact, two post-hoc sensitivity  
191 analyses on the primary endpoint were conducted. Both imputed data in subjects who stopped  
192 reporting symptoms prior to day 14. The first analysis used the last observation carried forward



193 as a worst-case scenario to impute missing symptoms while the second imputed “no symptom”  
194 when symptoms were missing as a best-case scenario. All statistical tests were two-sided and  
195 conducted at the 0.05 significance level. Statistical analyses were done using SAS version 9.4.

196

197

## 198 **RESULTS**

199 The study flow-chart is shown in figure 1. 217 subjects were enrolled and there was one screen-  
200 fail due to administration of COVID-19 vaccine prior to randomization. 216 subjects were  
201 randomized into the study with 109 assigned to placebo and 107 to hesperidin. All participants  
202 who received the placebo completed the study, but there was one lost to follow-up in the  
203 hesperidin group.

204

205 **Figure 1.** Study flow chart.

206

### 207 Baseline characteristics (Table 1)

208 The demographics as well as the clinical profile at randomization are shown in table 1.  
209 For the whole study population, mean age was  $40.98 \pm 12.14$  years with a proportion of males of  
210 44.9%. The delay between the beginning of symptoms and randomization in the placebo group  
211 and the hesperidin group was similar at  $3.78 \pm 1.81$  and  $3.88 \pm 1.89$  days respectively. The mean  
212 delay between COVID-19 diagnosis and randomization was  $1.10 \pm 0.43$  days in the placebo and  
213  $1.10 \pm 0.39$  days in the hesperidin group. The most common COVID-19 symptoms in decreasing  
214 frequency were: cough (53.2%), general weakness (44.9%), headache (42.6%), pain (35.2%),  
215 sore throat (28.7%), runny nose (26.9%), chills (22.7%), shortness of breath (22.2%), anosmia  
216 (18.5%), fever (16.2%), diarrhea (6.9%), nausea/vomiting (6.5%) and irritability/confusion

217 (3.2%). This was a low-risk population evidenced by the low prevalence of diabetes,  
 218 hypertension, heart diseases and respiratory diseases.

219

220 **Table 1. Patients' baseline characteristics, intent-to-treat population**

	<b>Placebo N = 109</b>	<b>Hesperidin N = 107</b>	<b>All N = 216</b>
<b>Age (years)</b>	40.67 ± 11.26	41.31 ± 13.02	40.98 ± 12.14
<b>Male</b>	49 (45.0%)	48 (44.9%)	97 (44.9%)
<b>BMI (kg/m<sup>2</sup>)</b>	28.21 ± 6.82	28.12 ± 6.38	28.16 ± 6.59
<b>Delay from symptoms to randomization (days)</b>	3.78 ± 1.81	3.88 ± 1.89	3.83 ± 1.84
<b>Delay from diagnosis to randomization (days)</b>	1.10 ± 0.43	1.10 ± 0.39	1.10 ± 0.41
<b>COVID-19 symptoms</b>			
Cough	55 (50.5%)	60 (56.1%)	115 (53.2%)
General weakness	49 (45.0%)	48 (44.9%)	97 (44.9%)
Headache	45 (41.3%)	47 (43.9%)	92 (42.6%)
Pain	39 (35.8%)	37 (34.6%)	76 (35.2%)
Sore throat	28 (25.7%)	34 (31.8%)	62 (28.7%)
Runny nose	24 (22.0%)	34 (31.8%)	58 (26.9%)
Chills	21 (19.3%)	28 (26.2%)	49 (22.7%)
Shortness of breath	20 (18.3%)	28 (26.2%)	48 (22.2%)
Anosmia	20 (18.3%)	20 (18.7%)	40 (18.5%)
Fever	17 (15.6%)	18 (16.8%)	35 (16.2%)
Diarrhea	6 (5.5%)	9 (8.4%)	15 (6.9%)
Nausea/Vomiting	8 (7.3%)	6 (5.6%)	14 (6.5%)
Irritability/Confusion	5 (4.6%)	2 (1.9%)	7 (3.2%)
<b>Risk factors</b>			
Diabetes	1 (0.9%)	6 (5.6%)	7 (3.2%)
Hypertension	9 (8.3%)	14 (13.1%)	23 (10.6%)
Heart diseases	0 (0%)	0 (0%)	0 (0%)
Stroke	0 (0%)	0 (0%)	0 (0%)
Respiratory diseases	18 (16.5%)	15 (14.0%)	33 (15.3%)
- Asthma	17	14	31
- COPD	1	0	1
- Pulmonary fibrosis	0	1	1

221

222 Primary endpoint: proportion of participants with group A symptoms at day 3, 7, 10 and 14

223 (Table 2).

224 The proportion of subjects presenting with any of the four selected group A symptoms  
 225 (fever, cough, shortness of breath and anosmia) in the hesperidin group compared to the placebo  
 226 group were, respectively, 88.5% vs 88.8% (day 1), 91.2% vs 87.4% (day 3), 81.3% vs 75.2%  
 227 (day 7), 64.4% vs 60.6% (day 10) and 49.4% vs 58.5% (day 14). At 14 days, there was a 9.1%  
 228 absolute reduction in group A symptoms in the hesperidin group (OR: 0.69, p = 0.2328). There  
 229 was progressive attrition in the number of participants that reported their symptoms between day  
 230 1 and day 14, with 15 missing in the placebo group and 28 in the hesperidin group. In the first  
 231 post-hoc sensitivity analysis using the last observation carried forward imputation, there was also  
 232 no statistically significant difference in the primary endpoint at each time point (S2 table). In this  
 233 worst-case analysis, we still observed a reduction at day 14 in the hesperidin subjects from 59.3%  
 234 to 52.3%, a 7.0 % difference (OR 0.75, p = 0.3098). In the second post-hoc sensitivity analysis  
 235 imputing “no symptom” to any missing value (S2 table), the hesperidin group shows a  
 236 statistically significant absolute reduction of 14.5 % of group A symptoms from 50.9% to 36.4%  
 237 (OR: 0.55, p = 0.0343).

238

239 **Table 2. Proportion of patients with group A COVID-19 symptoms, intent-to-treat**  
 240 **population**

	Placebo	Hesperidin	All	OR (95% CI) <sup>a</sup>	P-value <sup>a</sup>
<b>Day 1</b>	N = 107	N = 104	N = 211		
<b>No</b>	12 (11.2%)	12 (11.5%)	24 (11.4%)		
<b>Yes<sup>b</sup></b>	95 (88.8%)	92 (88.5%)	187 (88.6%)	0.97 (0.41; 2.28)	0.9413
<b>Day 3</b>	N = 103	N = 102	N = 205		
<b>No</b>	13 (12.6%)	9 (8.8%)	22 (10.7%)		
<b>Yes<sup>b</sup></b>	90 (87.4%)	93 (91.2%)	183 (89.3%)	1.49 (0.60; 3.69)	0.3849
<b>Day 7</b>	N = 101	N = 91	N = 192		
<b>No</b>	25 (24.8%)	17 (18.7%)	42 (21.9%)		
<b>Yes<sup>b</sup></b>	76 (75.2%)	74 (81.3%)	150 (78.1%)	1.43 (0.71; 2.88)	0.3139

<b>Day 10</b>	N = 99	N = 90	N = 189		
<b>No</b>	39 (39.4%)	32 (35.6%)	71 (37.6%)		
<b>Yes<sup>b</sup></b>	60 (60.6%)	58 (64.4%)	118 (62.4%)	1.18 (0.65; 2.14)	0.5886
<b>Day 14</b>	N = 94	N = 79	N = 173		
<b>No</b>	39 (41.5%)	40 (50.6%)	79 (45.7%)		
<b>Yes<sup>b</sup></b>	55 (58.5%)	39 (49.4%)	94 (54.3%)	0.69 (0.38; 1.27)	0.2328

241 <sup>a</sup>Comparison between placebo group and hesperidin group. Significant when  $p < 0.05$

242 <sup>b</sup>Subject has at least one of the group A COVID-19 symptoms: Fever, cough, shortness of breath or  
243 anosmia

244 N represents the number of subjects who completed the daily symptom diary.

245

#### 246 Effect of hesperidin treatment on the number of COVID-19 symptoms at day 3, 7, 10 and 14.

247 Figure 2 presents the effect of hesperidin on the number of COVID-19 symptoms at day  
248 1, 3, 7, 10 and 14. Hesperidin did not improve the mean number of COVID-19 symptoms for the  
249 whole treatment duration: day 1:  $5.10 \pm 2.26$  vs  $5.48 \pm 2.35$ ; day 3:  $4.16 \pm 2.39$  vs  $4.74 \pm 2.52$ ;  
250 day 7:  $2.96 \pm 2.46$  vs  $3.13 \pm 2.49$ ; day 10:  $1.95 \pm 2.12$  vs  $2.01 \pm 2.19$ ; day 14:  $1.40 \pm 1.65$  vs  $1.38$   
251  $\pm 1.76$  in placebo vs hesperidin group respectively.

252

253 **Figure 2.** Mean number of COVID-19 symptoms at day 1, 3, 7, 10 and 14 in the placebo and the  
254 hesperidin groups. Values are mean  $\pm$  SD.

255

#### 256 Effect of hesperidin treatment on the duration of COVID-19 symptoms.

257 The Kaplan-Meier curve showing the proportion of symptom-free subjects over 14 days is  
258 shown in figure 3. Fourteen days post randomization, only 31.1% patients in the placebo group  
259 and 27.4% in the hesperidin group were symptom-free, indicating that the health of about 70% of  
260 our participants was still impacted by COVID-19 infection 14 days after study randomization and  
261 about 18 days after the beginning of symptoms. There was no difference in time to complete  
262 disappearance of symptoms between the two groups ( $p = 0.8834$ ). In subjects with complete

263 disappearance of symptoms, the duration of all COVID-19 symptoms in the placebo group vs the  
264 hesperidin group defined as the number of days between randomization and complete  
265 disappearance of any symptom was similar in both groups at  $9.88 \pm 2.71$  days with placebo vs  
266  $10.34 \pm 3.15$  days with hesperidin.

267

268 **Figure 3:** Kaplan-Meier curve. Proportion of symptom-free subjects over 14 days in the ITT  
269 population in the placebo and the hesperidin groups.

270

271 Effect of hesperidin therapy on the proportion of subjects with each COVID-19 symptom and on  
272 the composite of hospital admission, mechanic ventilation and death.

273 Figure 4 presents the proportion of subjects with each of the thirteen selected COVID-19  
274 symptoms at day 1, 3, 7, 10 and 14. Detailed data and statistics for each symptom at each time  
275 point are presented in S3 tables. The four graphs in the top row of figure 4 represent the group A  
276 symptoms. The results showed that, except for fever which was absent at day 14 in the hesperidin  
277 group, each COVID-19 symptom was present at each time point in a certain proportion of patient  
278 that greatly varies depending on the symptom. For the whole duration of the study, the most  
279 prominent symptoms for their frequency and duration were cough and anosmia, two group A  
280 symptoms which affected 60.8% and 43.9% of participants at day 1 and persisted in 28.7% and  
281 29.3% of them, respectively, at day 14. Some other symptoms such as runny nose, shortness of  
282 breath/difficulty breathing, headache and general weakness were still present in more than 10%  
283 of the whole population at the end of the study. All other symptoms were markedly reduced with  
284 time and only affected a small proportion of patient at day 14. For each time point, hesperidin had  
285 no statistically significant impact on the proportion of patients with each of these thirteen  
286 COVID-19 symptoms compared to the placebo group. Anosmia, the most frequently persisting

287 symptom was the only symptom to increase during the time course of the study as 54.1% of the  
288 whole study group was affected at day 3. At day 14, persisting anosmia was reduced by 7.3% in  
289 the hesperidin group (25.3%) compared to the placebo group (32.6%, OR 0.70 [0.36 – 1.37],  $p =$   
290 0.2952).

291  
292 **Figure 4.** Proportion of subjects with each of thirteen COVID-19 symptoms at day 1, 3, 7, 10  
293 and 14 in the placebo and the hesperidin groups.

294  
295 The composite of COVID-19 related hospitalization, mechanic ventilation or death in the 14 days  
296 following randomization occurred in 1 subject in the placebo group and 3 subjects in the  
297 hesperidin group ( $p = 0.3669$ ). One placebo subject was hospitalized for COVID-19 pneumonia  
298 that required intubation and ventilation. In the hesperidin group, 2 participants were hospitalized  
299 with pneumonia not requiring mechanical ventilation, and 1 subject was hospitalized for  
300 pneumonia and dehydration. There was no death.

301  
302 Safety profile of hesperidin

303 Treatment emergent adverse events (AE) and treatment emergent serious adverse events  
304 (TESAE) are presented in S4 table. There were 16 adverse events in the placebo group and 23 in  
305 the hesperidin group. Two subjects experienced at least one severe AE in the placebo group and 3  
306 subjects in the hesperidin group. AE possibly related to study treatment occurred in 4 placebo  
307 participants and in 3 hesperidin participants. The majority of AE were related to COVID-19  
308 infection. AE led to study drug withdrawal in 5 placebo subjects and 8 hesperidin subjects. There  
309 was 1 TESAE in the placebo group and 4 in the hesperidin group and none were related to study  
310 treatment.

311

## 312 **DISCUSSION**

313 Commonly reported COVID-19 symptoms are cough, fever, malaise and anosmia [3, 4].

314 More severe cases present an exaggerated inflammatory response depicted as a cytokine storm

315 that can lead to respiratory distress [6, 7]. Because SARS-CoV-2 is an evolutive virus with

316 possible emergence of new variants that may not respond to current vaccines, it remains

317 imperative to find treatments to reduce disease severity. Symptoms associated with COVID-19 in

318 non-hospitalized subjects can be responsible for substantial disability, absenteeism, and loss of

319 productivity [16]. During the first and second waves of the pandemic, availability of COVID-19

320 PCR diagnosis was limited and restricted to more symptomatic subjects, therefore introducing a

321 selection bias in studies evaluating symptoms. During the recent third wave of the pandemic,

322 PCR testing for COVID-19 became widely available and testing was strongly encouraged for all

323 symptomatic subjects and contacts. There has been no prospective evaluation of COVID-19

324 symptoms in non-hospitalized and non-vaccinated subjects during the third wave. Here, we

325 prospectively evaluated COVID-19 symptoms and the effects of 14-days hesperidin therapy, a

326 flavonoid naturally present in citrus fruits, in 216 non-hospitalized and non-vaccinated

327 symptomatic subjects who tested positive for COVID-19.

328

329 Frequency and evolution of COVID-19 symptoms during the third wave. Subjects in this trial

330 were randomized a mean of  $3.83 \pm 1.84$  days after the beginning of symptoms and a mean of  $1.10$

331  $\pm 0.41$  days after PCR diagnosis and followed for 14 days. Therefore, at the end of the study, the

332 participants were at about 18 days since the beginning of symptoms. At randomization the most

333 frequent symptoms, present in more than 1/3 of subjects, were cough, general weakness,

334 headache and pain. In 20%-30% there was sore throat, runny nose, chills and shortness of breath.

335 Anosmia was present in 18.5% and fever in only 16.2%. Other symptoms, diarrhea,  
336 nausea/vomiting and irritability/confusion were present in only a minority of patients in a  
337 proportion of less than 7% each. With the notable exception of anosmia, all symptoms steadily  
338 decreased in frequency with time as the mean number of symptoms went from about 5.3 to 1.4  
339 from day 1 to day 14. Still, most subjects, about 70%, remained symptomatic at day 14. The  
340 proportion of subjects with anosmia tripled from randomization to day 3 when it reached a  
341 proportion of 54.1%. At day 14, anosmia was the most frequent persisting symptom (29.3%).  
342 Considering the previous reports on the importance of persisting anosmia after COVID-19 and its  
343 impact on quality of life, our study confirms that anosmia occurs in about 50% of infected  
344 subjects and persists more than 14 days in about 30%. Clearly, because of its clinical importance,  
345 new sudden onset anosmia represents the best objective symptomatic target for COVID-19  
346 therapeutic studies.

347         The incidence of fever found in this study is much lower than what has been previously  
348 reported early in the pandemic [17], but confirms later reports in non-hospitalized COVID-19  
349 subjects that found comparable incidence [18]. Indeed, in 4066 outpatient adults with COVID-19  
350 diagnosis and a mean age of 43, 10.3% reported fever [18]. This rate is similar to the 16.2%  
351 found at randomization in our study as self-reported by the participants. Our study further  
352 emphasizes the discrepancy in self-reported fever and mandatory measured temperature since we  
353 provided the subjects with a thermometer and required daily temperature measurements. Baseline  
354 temperature at randomization was inquired by phone, while day 1 temperature was measured  
355 with the provided electronic thermometer and entered in the symptoms log. Fever measured on  
356 day 1 in our study (defined as greater than 38.0 by oral thermometer) was present in only 3.9% of  
357 subjects, yet 32% reported chills on day 1 in the symptoms log. Our study therefore shows that



358 objective fever is rare in most non-hospitalized COVID-19 subjects about 4 days after the  
359 beginning of symptoms.

360  
361 Effects of hesperidin therapy on COVID-19 symptoms. The primary endpoint of this trial was the  
362 proportion of subjects with any of 4 cardinal COVID-19 symptoms: fever, cough, shortness of  
363 breath and new onset anosmia. In the province of Quebec, Canada, they were referred to as group  
364 A symptoms, being more frequent and considered more specific for COVID-19 diagnosis. These  
365 symptoms were used for epidemiological diagnosis of COVID-19 contacts when large scale PCR  
366 testing was not available. Group A symptoms were present in 88.6% of patients on day 1 (88.8%  
367 placebo and 88.5% hesperidin) and persisted in 54.3% of patients on day 14. At day 14,  
368 hesperidin reduced group A symptoms by 8.9% from 58.5% in the placebo group to 49.4%  
369 without reaching statistical significance (OR 0.69,  $p = 0.23$ ).

370 Despite repeated recalls by phone and emails, there was progressive attrition in the  
371 number of participants reporting symptoms, greater in the hesperidin group (28/107) than in the  
372 placebo group (15/109). To account and explore the extremes of a possible attrition bias, we  
373 performed a worst-case and best-case imputation analysis to missing values. In the worst-case  
374 analysis, we imputed the “last observation carried forward” approach and symptomatic subjects  
375 were therefore considered symptomatic for all subsequent missing days. In the best-case analysis,  
376 we imputed the absence of symptom to all missing values. In the worst-case analysis, we found  
377 no statistically significant difference in group A symptoms at all time points, but still observed a  
378 reduction at day 14 in the hesperidin group from 59.3% to 52.3%, a 7.0 % difference (OR 0.75,  $p$   
379 = 0.3098). In the best-case analysis, the difference at day 14 became significant with a reduction  
380 of 14.5% from 50.9% in the placebo group to 36.4% in the hesperidin group (OR 0.55,  $p =$   
381 0.0343). Although speculative, the reason for the greater attrition rate in the reporting of

382 symptoms in the hesperidin group may be due to symptomatic improvement and decreased  
383 willingness to cooperate for the participants that felt better. The attrition rate increased with study  
384 duration, a recognized factor of poorer compliance. Our study, powered to detect a 20% absolute  
385 difference in symptoms at Day 7, did not find statistically significant differences between  
386 treatments. A smaller absolute reduction, especially for anosmia, could however be highly  
387 clinically significant. Based on the attrition bias analysis and a best-case scenario where non-  
388 compliant subjects have no symptom, we cannot exclude that hesperidin could have beneficial  
389 effects and further studies are encouraged. Because of its clinical importance, persistence, and  
390 more subjective evaluation, new onset anosmia should be a primary therapeutic target in COVID-  
391 19 therapeutic studies.

392

393       The rationale and interest for using hesperidin in the treatment and even in the prevention  
394 of COVID-19 has been highlighted by others, both for its anti-oxidant and anti-inflammatory  
395 properties, and for its ability to block the entry and replication of SARS-CoV-2 [19, 20]. The  
396 current phase 2 study does not close the chapter on hesperidin therapy for COVID-19 with a  
397 signal of possible benefit on selected symptoms driven by a reduction of anosmia. Furthermore,  
398 since we did not grade the severity of each symptom in the design of this trial, we cannot exclude  
399 a potential benefit of treatment on this important component. Besides the attrition bias discussed  
400 above, there are several limitations that need to be considered in the planning of future phase 3  
401 studies: delay of treatment, dosing, and duration of treatment and follow-up. The mean delay of  
402  $3.83 \pm 1.84$  days before enrollment into the trial may certainly mitigate the benefits of therapy as  
403 it has been largely reported that viral load peaks at symptoms onset and for the few following  
404 days, which is concordant with the infectiousness profile of COVID-19 [21]. The optimal  
405 therapeutic dosage of hesperidin has not previously been reported in human subjects. Participants

406 were asked to take 2 capsules of 500 mg each once daily, the maximal allowable daily dose by  
407 the Non-Prescription and Natural Health Products Directorate (NNHPD) of Canada. Higher  
408 dosage more than once a day may be necessary to obtain optimal therapeutic effects. Finally, the  
409 duration of therapy and of follow-up may need to be longer to provide maximal benefit and better  
410 detect improvement of persisting symptoms, especially anosmia.

411 Our study showed good safety of hesperidin with no evidence for greater drug-related AE  
412 compared to placebo and no drug-related SAE. This concords with previous pre-clinical  
413 observations in Sprague Dawley rats, with low observed adverse effects at a dosage of 1000  
414 mg/kg in a sub-chronic oral toxicity study [22]. As well, human studies showed a safe profile of  
415 hesperidin at a dosage ranging from 500 mg daily for 3 weeks [23] to 800 mg daily for up to 4  
416 weeks [24] in both men and women. Although we excluded pregnant women from the current  
417 study, the use of veinotonics containing hesperidin to treat hemorrhoids and varices in pregnant  
418 women appears safe with no increase in reported adverse outcomes [25]. Finally, the US Food  
419 and Drug Administration issued a Generally Recognized as Safe Notice (GRAS No.796) in 2018  
420 [26] for the use of orange extract with 85% hesperidin content as well as GRAS No. 901 [27] for  
421 glucosyl hesperidin to be used as additives in food and beverages. Collectively, these data  
422 support the use of higher dosage of hesperidin in future trials.

423

424

## 425 **Conclusion**

426 During the third wave of the COVID-19 pandemic, only 30% of initially symptomatic  
427 non-hospitalized and non-vaccinated subjects were asymptomatic about 18 days after symptom  
428 onset. Anosmia affected 50% of subjects and was the most frequently persisting symptom in  
429 30%. Hesperidin therapy is safe and may help reduce a composite of selected COVID-19

430 symptoms including fever, cough, shortness of breath and anosmia. Further trials with this agent

431 are encouraged.

432

433

434 **Acknowledgements**

435         The authors would like to thank: The Montreal Heart Institute Foundation for providing  
436 funding for this study; Sarah Samson RN, Denis Fortin RN, Cyntia Pennestri RN, Colette Morin  
437 RN, Natasha Moisan RN, Patricia-Iva Blaise RN, Nancy Fernandez RN, Jessica Drouin RN,  
438 Amélie Allard LPN, Ramona Badaluta RN, Myriam Duhamel RN, Marie-Gabrielle Lessard RN  
439 and Alexandre Bergeron from the Montreal Heart Institute clinical study team for their hard work  
440 in recruiting and following-up participants during the whole study; pharmacists Marie Robitaille,  
441 Lucie Verret, Sylvia Audet, Arnaud Canneva and Jeannie Meideros Charbonneau and pharmacy  
442 technicians from the Montreal Heart Institute pharmacy study team; the biostatistician and project  
443 management teams at the Montreal Health Innovations Coordinating Center for their expertise in  
444 development and project management, as well as statistical analyses; Chantal Lacoste for her  
445 help in setting up the telephone system for remote monitoring of participants; and the telephone  
446 operators who initiated first contact with the study participants; Alberto Mazza and Caroline  
447 Morneau for multiple insightful discussions on the scientific rationale supporting the hesperidin  
448 clinical study; the Montreal Heart Institute Foundation for the financial support through  
449 donations by the Ariane Riou and Réal Plourde Foundation, the Sandra and Alain Bouchard  
450 Foundation, the Lise and Richard Fortin Foundation and Jacques D'Amours; Valeo Pharma Inc.  
451 for providing the study drug and placebo free of charge.

## 452 **References**

- 453 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from  
454 Patients with Pneumonia in China, 2019. *N Engl J Med.* 2020;382(8):727-33. Epub 2020/01/25.  
455 doi: 10.1056/NEJMoa2001017. PubMed PMID: 31978945; PubMed Central PMCID:  
456 PMCPMC7092803.
- 457 2. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al.  
458 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically  
459 Proven Protease Inhibitor. *Cell.* 2020;181(2):271-80 e8. Epub 2020/03/07. doi:  
460 10.1016/j.cell.2020.02.052. PubMed PMID: 32142651; PubMed Central PMCID:  
461 PMCPMC7102627.
- 462 3. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A  
463 systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. *J Med*  
464 *Virol.* 2021;93(3):1449-58. Epub 2020/08/14. doi: 10.1002/jmv.26424. PubMed PMID:  
465 32790106; PubMed Central PMCID: PMCPMC7436673.
- 466 4. Beltran-Corbellini A, Chico-Garcia JL, Martinez-Poles J, Rodriguez-Jorge F, Natera-  
467 Villalba E, Gomez-Corral J, et al. Acute-onset smell and taste disorders in the context of COVID-  
468 19: a pilot multicentre polymerase chain reaction based case-control study. *Eur J Neurol.*  
469 2020;27(9):1738-41. Epub 2020/04/23. doi: 10.1111/ene.14273. PubMed PMID: 32320508;  
470 PubMed Central PMCID: PMCPMC7264557.
- 471 5. Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL.  
472 Smell dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol.* 2020;10(8):944-50.  
473 Epub 2020/04/18. doi: 10.1002/alr.22587. PubMed PMID: 32301284; PubMed Central PMCID:  
474 PMCPMC7262123.
- 475 6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected  
476 with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497-506. Epub  
477 2020/01/28. doi: 10.1016/S0140-6736(20)30183-5. PubMed PMID: 31986264; PubMed Central  
478 PMCID: PMCPMC7159299.
- 479 7. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-  
480 reactive protein, and procalcitonin in patients with COVID-19. *J Clin Virol.* 2020;127:104370.  
481 Epub 2020/04/29. doi: 10.1016/j.jcv.2020.104370. PubMed PMID: 32344321; PubMed Central  
482 PMCID: PMCPMC7194648.
- 483 8. Lin CW, Tsai FJ, Tsai CH, Lai CC, Wan L, Ho TY, et al. Anti-SARS coronavirus 3C-like  
484 protease effects of *Isatis indigotica* root and plant-derived phenolic compounds. *Antiviral Res.*  
485 2005;68(1):36-42. Epub 2005/08/24. doi: 10.1016/j.antiviral.2005.07.002. PubMed PMID:  
486 16115693; PubMed Central PMCID: PMCPMC7114321.
- 487 9. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets  
488 for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta*  
489 *Pharmaceutica Sinica B.* 2020. doi: <https://doi.org/10.1016/j.apsb.2020.02.008>.
- 490 10. Ding Z, Sun G, Zhu Z. Hesperidin attenuates influenza A virus (H1N1) induced lung  
491 injury in rats through its anti-inflammatory effect. *Antivir Ther.* 2018;23(7):611-5. Epub  
492 2018/04/07. doi: 10.3851/IMP3235. PubMed PMID: 29623897.
- 493 11. Ma H, Feng X, Ding S. Hesperetin attenuates ventilator-induced acute lung injury through  
494 inhibition of NF-kappaB-mediated inflammation. *Eur J Pharmacol.* 2015;769:333-41. Epub  
495 2015/11/28. doi: 10.1016/j.ejphar.2015.11.038. PubMed PMID: 26610718.

- 496 12. Ye J, Guan M, Lu Y, Zhang D, Li C, Li Y, et al. Protective effects of hesperetin on  
497 lipopolysaccharide-induced acute lung injury by targeting MD2. *Eur J Pharmacol.* 2019;852:151-  
498 8. Epub 2019/02/27. doi: 10.1016/j.ejphar.2019.02.042. PubMed PMID: 30807747.
- 499 13. Hajjalyani M, Hosein Farzaei M, Echeverria J, Nabavi SM, Uriarte E, Sobarzo-Sanchez  
500 E. Hesperidin as a Neuroprotective Agent: A Review of Animal and Clinical Evidence.  
501 *Molecules.* 2019;24(3). Epub 2019/02/15. doi: 10.3390/molecules24030648. PubMed PMID:  
502 30759833; PubMed Central PMCID: PMC6384806.
- 503 14. Chanet A, Milenkovic D, Manach C, Mazur A, Morand C. Citrus flavanones: what is their  
504 role in cardiovascular protection? *J Agric Food Chem.* 2012;60(36):8809-22. Epub 2012/05/12.  
505 doi: 10.1021/jf300669s. PubMed PMID: 22574825.
- 506 15. Testai L, Calderone V. Nutraceutical Value of Citrus Flavanones and Their Implications  
507 in Cardiovascular Disease. *Nutrients.* 2017;9(5). Epub 2017/05/17. doi: 10.3390/nu9050502.  
508 PubMed PMID: 28509871; PubMed Central PMCID: PMC65452232.
- 509 16. Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom  
510 Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-  
511 19 in a Multistate Health Care Systems Network - United States, March-June 2020. *MMWR*  
512 *Morb Mortal Wkly Rep.* 2020;69(30):993-8. Epub 2020/07/31. doi: 10.15585/mmwr.mm6930e1.  
513 PubMed PMID: 32730238; PubMed Central PMCID: PMC7392393  
514 Journal Editors form for disclosure of potential conflicts of interest. Christopher J. Lindsell reports grants from  
515 National Institutes of Health and Department of Defense, and contracts with the Marcus  
516 Foundation, CDC, Endpoint Health, Entegriion, bioMerieux, and Bioscape Digital, outside the  
517 submitted work. Daniel J. Henning reports personal fees from CytoVale and grants from Baxter,  
518 outside the submitted work. Akram Khan reports grants from United Therapeutics, Actelion  
519 Pharmaceuticals, Regeneron, and Reata Pharmaceuticals, outside the submitted work. Samuel M.  
520 Brown reports grants from National Institutes of Health, Department of Defense, Intermountain  
521 Research and Medical Foundation, and Janssen, consulting fees paid to his employer from Faron  
522 and Sedana, and royalties from Oxford University Press, outside the submitted work. Ithan D.  
523 Peltan reports grants from National Institutes of Health, Asahi Kasei Pharma, Immunexpress Inc.,  
524 Janssen Pharmaceuticals, and Regeneron, outside the submitted work. Todd W. Rice reports  
525 personal fees from Cumberland Pharmaceuticals, Inc., Cytovale, Inc., and Avisia, LLC, outside  
526 the submitted work. No other potential conflicts of interest were disclosed.
- 527 17. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of  
528 coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. *J Infect.*  
529 2020;80(6):656-65. Epub 2020/04/14. doi: 10.1016/j.jinf.2020.03.041. PubMed PMID:  
530 32283155; PubMed Central PMCID: PMC7151416.
- 531 18. Mizrahi B, Shilo S, Rossman H, Kalkstein N, Marcus K, Barer Y, et al. Longitudinal  
532 symptom dynamics of COVID-19 infection. *Nat Commun.* 2020;11(1):6208. Epub 2020/12/06.  
533 doi: 10.1038/s41467-020-20053-y. PubMed PMID: 33277494; PubMed Central PMCID:  
534 PMC7718370.
- 535 19. Bellavite P, Donzelli A. Hesperidin and SARS-CoV-2: New Light on the Healthy  
536 Function of Citrus Fruits. *Antioxidants (Basel).* 2020;9(8). Epub 2020/08/23. doi:  
537 10.3390/antiox9080742. PubMed PMID: 32823497; PubMed Central PMCID:  
538 PMC7465267.
- 539 20. Haggag YA, El-Ashmawy NE, Okasha KM. Is hesperidin essential for prophylaxis and  
540 treatment of COVID-19 Infection? *Med Hypotheses.* 2020;144:109957. Epub 2020/06/13. doi:  
541 10.1016/j.mehy.2020.109957. PubMed PMID: 32531538; PubMed Central PMCID:  
542 PMC7274964.



- 543 21. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral  
544 shedding and transmissibility of COVID-19. *Nat Med*. 2020. Epub 2020/04/17. doi:  
545 10.1038/s41591-020-0869-5. PubMed PMID: 32296168.
- 546 22. Li Y, Kandhare AD, Mukherjee AA, Bodhankar SL. Acute and sub-chronic oral toxicity  
547 studies of hesperidin isolated from orange peel extract in Sprague Dawley rats. *Regul Toxicol*  
548 *Pharmacol*. 2019;105:77-85. Epub 2019/04/17. doi: 10.1016/j.yrtph.2019.04.001. PubMed  
549 PMID: 30991075.
- 550 23. Rizza S, Muniyappa R, Iantorno M, Kim JA, Chen H, Pullikotil P, et al. Citrus polyphenol  
551 hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial  
552 function and reducing inflammatory markers in patients with metabolic syndrome. *J Clin*  
553 *Endocrinol Metab*. 2011;96(5):E782-92. Epub 2011/02/25. doi: 10.1210/jc.2010-2879. PubMed  
554 PMID: 21346065; PubMed Central PMCID: PMC3085197.
- 555 24. Demonty I, Lin Y, Zebregs YE, Vermeer MA, van der Knaap HC, Jakel M, et al. The  
556 citrus flavonoids hesperidin and naringin do not affect serum cholesterol in moderately  
557 hypercholesterolemic men and women. *J Nutr*. 2010;140(9):1615-20. Epub 2010/07/28. doi:  
558 10.3945/jn.110.124735. PubMed PMID: 20660284.
- 559 25. Lacroix I, Beau AB, Hurault-Delarue C, Bouilhac C, Petiot D, Vayssiere C, et al. First  
560 epidemiological data for venotonics in pregnancy from the EFEMERIS database. *Phlebology*.  
561 2016;31(5):344-8. Epub 2015/06/11. doi: 10.1177/0268355515589679. PubMed PMID:  
562 26060062.
- 563 26. GRAS Notice (GRN) No. 796 [Internet]. Available from:  
564 <https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory>.
- 565 27. GRAS Notice (GRN) No. 901 [Internet]. Available from:  
566 <https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory>.
- 567
- 568



569 **Supporting information caption**

570 **S1 Protocol. Version 2.0 of the Hesperidin study protocol approved by the Montreal Heart**

571 **Institute Research and Ethics Committees**

572

573 **S2 table. Proportion of patients with group A COVID-19 symptoms**

574 **– Attrition bias analysis**

575

576 **S3 table. Summary of and statistical analysis for the presence of each 13 COVID-19**

577 **symptoms**

578

579 **S4 table. Overall summary of treatment emergent adverse events (TEAE) and serious**

580 **adverse events (TESAE)**

581

582 **S5 CONSORT 2010 checklist.**


583

584


585




## CONSORT 2010 Flow Diagram



Number of Covid-19 symptoms





100 100 100 100 97 93 90 85 85 83 81 73 70 66 55  
 100 100 100 104 102 102 101 95 93 90 84 82 79 72 66

